On June 14, Kyverna Therapeutics hosted an industry symposium at EULAR in Vienna with a data update on KYV-101, its lead CAR T-cell therapy candidate. In the data presentation, Kyverna said early KYV-101 data demonstrate “promising” outcomes across multiple indications. In the KYV-101 CAR safety and efficacy experience from hematology, the company said CAR demonstrated an improved safety profile in a 20-patient study without compromising efficacy and that data supported dose-selection for the autoimmune disease setting. In myasthenia gravis, within 60 days of infusion, improved symptoms and mobility were observed, Kyverna says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics Showcases CAR T-cell Therapy Progress at EULAR
- J.P. Morgan Predicts up to 210% Gains for These 2 ‘Strong Buy’ Stocks
- Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
- Kyverna Therapeutics reports Q1 EPS ($1.12), consensus (84c)
- Kyverna Therapeutics added to Analyst Focus List at JPMorgan